The infectious disease diagnostics testing market size has grown rapidly in recent years. It will grow from $42.24 billion in 2025 to $46.48 billion in 2026 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing prevalence of infectious diseases, rising incidence of respiratory infections, expansion of diagnostic laboratory infrastructure, growing awareness of early disease diagnosis, increased government focus on disease control.
The infectious disease diagnostics testing market size is expected to see strong growth in the next few years. It will grow to $65.49 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to rising risk of global pandemics, increasing demand for rapid diagnostic solutions, growing investments in healthcare diagnostics, expanding disease surveillance programs, rising burden of tropical and viral diseases. Major trends in the forecast period include rising demand for rapid and early infectious disease detection, growing adoption of point of care infectious disease tests, increasing use of molecular diagnostics for pathogen identification, expansion of diagnostic testing for emerging and re-emerging infections, growing focus on large-scale disease screening and surveillance.
The infectious disease diagnostic testing market is anticipated to experience growth due to an increase in respiratory infections. Respiratory infections affect various parts of the respiratory system and are caused by viral and bacterial transmission through close contact, poor hygiene, crowded living conditions, and seasonal variations. Diagnostic testing for infectious diseases is crucial for accurate identification and treatment of respiratory infections, enabling the precise detection of pathogens such as viruses and bacteria in patient samples. For example, hospitalizations for acute upper respiratory infections saw a 32% increase from 2,114 cases in 2022 to 2,797 cases in 2023, as reported by the Canadian Institute for Health Information.
Major companies in the infectious disease diagnostic testing market are developing innovative technologies to rapidly and accurately detect critical infections. Infectious disease diagnostics involves identifying pathogens, such as bacteria, viruses, or parasites, to guide diagnosis and treatment. For example, in January 2025, QIAGEN, a Germany-based biotechnology company, launched new QIAstat-Dx syndromic testing panels in India, including the Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel, alongside the previously authorized Respiratory SARS-CoV-2 Panel, all approved by India's Central Drugs Standard Control Organization (CDSCO). The QIAstat-Dx system uses multiplex real-time PCR with single-use cartridges to detect multiple pathogens simultaneously, providing results in about an hour for gastrointestinal infections and 80 minutes for central nervous system infections. These panels improve diagnostic speed and accuracy compared to traditional methods, enabling timely treatment, enhancing patient outcomes, and reducing healthcare system burdens. The system also offers configurable setups and cloud connectivity for remote monitoring and efficient data management.
In July 2024, Roche, a Switzerland-based company, acquired the point-of-care technology business of LumiraDx for an undisclosed amount. Through this acquisition, Roche aimed to accelerate its growth in decentralized and primary-care testing by integrating LumiraDx’s multi-assay platform, which can perform immunoassay, clinical chemistry, and, with future development, molecular diagnostics. LumiraDx is a UK-based provider of infectious disease diagnostic testing.
Major companies operating in the infectious disease diagnostics testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC.
North America was the largest region in the infectious disease diagnostics testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease diagnostics testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease diagnostics testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created supply chain challenges and cost pressures in the infectious disease diagnostics testing market by increasing duties on reagents, diagnostic kits, laboratory instruments, and electronic components. These impacts have raised production and procurement costs, particularly affecting molecular diagnostics and point of care test segments, with north america and asia-pacific regions experiencing greater exposure due to reliance on imported consumables. Diagnostic laboratories and hospitals have faced pricing pressures and procurement delays. On the positive side, tariffs have encouraged local manufacturing, regional sourcing of test kits, and strengthened domestic diagnostic supply capabilities, supporting long-term market resilience.
The infectious disease diagnostics testing market research report is one of a series of new reports that provides infectious disease diagnostics testing market statistics, including infectious disease diagnostics testing industry global market size, regional shares, competitors with a infectious disease diagnostics testing market share, detailed infectious disease diagnostics testing market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease diagnostics testing industry. This infectious disease diagnostics testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infectious disease diagnostics testing involves identifying the presence of pathogens, such as bacteria, viruses, fungi, or parasites, in a patient's body. These tests are critical for diagnosing infectious diseases and making appropriate treatment decisions. They play a crucial role in controlling the spread of infectious diseases, guiding treatment choices, and monitoring outbreaks.
The main types of infectious disease diagnostics testing are molecular diagnostic tests and point-of-care tests (POCT) for infectious diseases. Molecular diagnostic testing refers to laboratory techniques that detect and analyze genetic material (DNA or RNA) to diagnose diseases, identify pathogens, and predict treatment responses. These tests find applications in areas such as respiratory infections, human immunodeficiency virus (HIV), healthcare-associated infections (HAIS), sexual health, tropical diseases, and liver diseases. They are utilized by various end-users including diagnostic laboratories, hospitals and clinics, academic research institutes, and other healthcare providers.
The infectious disease diagnostics testing market consists of revenues earned by entities by providing services such as laboratory testing, point-of-care testing, molecular diagnostics, immunoassays, and rapid diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease diagnostics testing market also includes sales of diagnostic kits, reagents, instruments, and software used for detecting and identifying infectious agents in patients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The infectious disease diagnostics testing market size is expected to see strong growth in the next few years. It will grow to $65.49 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to rising risk of global pandemics, increasing demand for rapid diagnostic solutions, growing investments in healthcare diagnostics, expanding disease surveillance programs, rising burden of tropical and viral diseases. Major trends in the forecast period include rising demand for rapid and early infectious disease detection, growing adoption of point of care infectious disease tests, increasing use of molecular diagnostics for pathogen identification, expansion of diagnostic testing for emerging and re-emerging infections, growing focus on large-scale disease screening and surveillance.
The infectious disease diagnostic testing market is anticipated to experience growth due to an increase in respiratory infections. Respiratory infections affect various parts of the respiratory system and are caused by viral and bacterial transmission through close contact, poor hygiene, crowded living conditions, and seasonal variations. Diagnostic testing for infectious diseases is crucial for accurate identification and treatment of respiratory infections, enabling the precise detection of pathogens such as viruses and bacteria in patient samples. For example, hospitalizations for acute upper respiratory infections saw a 32% increase from 2,114 cases in 2022 to 2,797 cases in 2023, as reported by the Canadian Institute for Health Information.
Major companies in the infectious disease diagnostic testing market are developing innovative technologies to rapidly and accurately detect critical infections. Infectious disease diagnostics involves identifying pathogens, such as bacteria, viruses, or parasites, to guide diagnosis and treatment. For example, in January 2025, QIAGEN, a Germany-based biotechnology company, launched new QIAstat-Dx syndromic testing panels in India, including the Gastrointestinal Panel 2 and Meningitis/Encephalitis Panel, alongside the previously authorized Respiratory SARS-CoV-2 Panel, all approved by India's Central Drugs Standard Control Organization (CDSCO). The QIAstat-Dx system uses multiplex real-time PCR with single-use cartridges to detect multiple pathogens simultaneously, providing results in about an hour for gastrointestinal infections and 80 minutes for central nervous system infections. These panels improve diagnostic speed and accuracy compared to traditional methods, enabling timely treatment, enhancing patient outcomes, and reducing healthcare system burdens. The system also offers configurable setups and cloud connectivity for remote monitoring and efficient data management.
In July 2024, Roche, a Switzerland-based company, acquired the point-of-care technology business of LumiraDx for an undisclosed amount. Through this acquisition, Roche aimed to accelerate its growth in decentralized and primary-care testing by integrating LumiraDx’s multi-assay platform, which can perform immunoassay, clinical chemistry, and, with future development, molecular diagnostics. LumiraDx is a UK-based provider of infectious disease diagnostic testing.
Major companies operating in the infectious disease diagnostics testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Grifols S.A., Hologic Inc., PerkinElmer Inc., bioMérieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., DiaSorin SpA (Luminex), Seegene Inc., Ortho Clinical Diagnostics Inc., OraSure Technologies Inc., Meridian Bioscience Inc., Trinity Biotech PLC.
North America was the largest region in the infectious disease diagnostics testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease diagnostics testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease diagnostics testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have created supply chain challenges and cost pressures in the infectious disease diagnostics testing market by increasing duties on reagents, diagnostic kits, laboratory instruments, and electronic components. These impacts have raised production and procurement costs, particularly affecting molecular diagnostics and point of care test segments, with north america and asia-pacific regions experiencing greater exposure due to reliance on imported consumables. Diagnostic laboratories and hospitals have faced pricing pressures and procurement delays. On the positive side, tariffs have encouraged local manufacturing, regional sourcing of test kits, and strengthened domestic diagnostic supply capabilities, supporting long-term market resilience.
The infectious disease diagnostics testing market research report is one of a series of new reports that provides infectious disease diagnostics testing market statistics, including infectious disease diagnostics testing industry global market size, regional shares, competitors with a infectious disease diagnostics testing market share, detailed infectious disease diagnostics testing market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease diagnostics testing industry. This infectious disease diagnostics testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infectious disease diagnostics testing involves identifying the presence of pathogens, such as bacteria, viruses, fungi, or parasites, in a patient's body. These tests are critical for diagnosing infectious diseases and making appropriate treatment decisions. They play a crucial role in controlling the spread of infectious diseases, guiding treatment choices, and monitoring outbreaks.
The main types of infectious disease diagnostics testing are molecular diagnostic tests and point-of-care tests (POCT) for infectious diseases. Molecular diagnostic testing refers to laboratory techniques that detect and analyze genetic material (DNA or RNA) to diagnose diseases, identify pathogens, and predict treatment responses. These tests find applications in areas such as respiratory infections, human immunodeficiency virus (HIV), healthcare-associated infections (HAIS), sexual health, tropical diseases, and liver diseases. They are utilized by various end-users including diagnostic laboratories, hospitals and clinics, academic research institutes, and other healthcare providers.
The infectious disease diagnostics testing market consists of revenues earned by entities by providing services such as laboratory testing, point-of-care testing, molecular diagnostics, immunoassays, and rapid diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease diagnostics testing market also includes sales of diagnostic kits, reagents, instruments, and software used for detecting and identifying infectious agents in patients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Infectious Disease Diagnostics Testing Market Characteristics
3. Infectious Disease Diagnostics Testing Market Supply Chain Analysis
4. Global Infectious Disease Diagnostics Testing Market Trends and Strategies
5. Infectious Disease Diagnostics Testing Market Analysis of End Use Industries
7. Global Infectious Disease Diagnostics Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Infectious Disease Diagnostics Testing Total Addressable Market (TAM) Analysis for the Market
9. Infectious Disease Diagnostics Testing Market Segmentation
10. Infectious Disease Diagnostics Testing Market Regional and Country Analysis
11. Asia-Pacific Infectious Disease Diagnostics Testing Market
12. China Infectious Disease Diagnostics Testing Market
13. India Infectious Disease Diagnostics Testing Market
14. Japan Infectious Disease Diagnostics Testing Market
15. Australia Infectious Disease Diagnostics Testing Market
16. Indonesia Infectious Disease Diagnostics Testing Market
17. South Korea Infectious Disease Diagnostics Testing Market
18. Taiwan Infectious Disease Diagnostics Testing Market
19. South East Asia Infectious Disease Diagnostics Testing Market
20. Western Europe Infectious Disease Diagnostics Testing Market
21. UK Infectious Disease Diagnostics Testing Market
22. Germany Infectious Disease Diagnostics Testing Market
23. France Infectious Disease Diagnostics Testing Market
24. Italy Infectious Disease Diagnostics Testing Market
25. Spain Infectious Disease Diagnostics Testing Market
26. Eastern Europe Infectious Disease Diagnostics Testing Market
27. Russia Infectious Disease Diagnostics Testing Market
28. North America Infectious Disease Diagnostics Testing Market
29. USA Infectious Disease Diagnostics Testing Market
30. Canada Infectious Disease Diagnostics Testing Market
31. South America Infectious Disease Diagnostics Testing Market
32. Brazil Infectious Disease Diagnostics Testing Market
33. Middle East Infectious Disease Diagnostics Testing Market
34. Africa Infectious Disease Diagnostics Testing Market
36. Infectious Disease Diagnostics Testing Market Competitive Landscape and Company Profiles
37. Infectious Disease Diagnostics Testing Market Other Major and Innovative Companies
40. Infectious Disease Diagnostics Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Infectious Disease Diagnostics Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses infectious disease diagnostics testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for infectious disease diagnostics testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infectious disease diagnostics testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Molecular Diagnostic Test; Point Of Care Tests (POCT) Infectious Disease Diagnostics Test2) By Application: Respiratory; Human Immunodeficiency Virus (HIV); Healthcare-Associated Infections (HAIs); Sexual Health; Tropical Diseases
3) By End-User: Diagnostic Laboratories; Hospitals And Clinics
Subsegments:
1) By Molecular Diagnostic Test: Polymerase Chain Reaction (PCR) Tests; Nucleic Acid Amplification Tests (NAATs)2) By Point Of Care Tests (POCT) Infectious Disease Diagnostics Test: Lateral Flow Assays; Rapid Antigen Tests; Immunoassays; Portable PCR
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; Becton Dickinson And Company; Quest Diagnostics Incorporated; Grifols S.A.; Hologic Inc.; PerkinElmer Inc.; bioMérieux SA; Quidel Corporation; Sysmex Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; DiaSorin SpA (Luminex); Seegene Inc.; Ortho Clinical Diagnostics Inc.; OraSure Technologies Inc.; Meridian Bioscience Inc.; Trinity Biotech PLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Infectious Disease Diagnostics Testing market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG
- Becton Dickinson And Company
- Quest Diagnostics Incorporated
- Grifols S.A.
- Hologic Inc.
- PerkinElmer Inc.
- bioMérieux SA
- Quidel Corporation
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- DiaSorin SpA (Luminex)
- Seegene Inc.
- Ortho Clinical Diagnostics Inc.
- OraSure Technologies Inc.
- Meridian Bioscience Inc.
- Trinity Biotech PLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 46.48 Billion |
| Forecasted Market Value ( USD | $ 65.49 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
